Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of coronary heart disease vaccine based on (M)T-DC (Target-dendritic cell) technology

A technology of T-DC and coronary heart disease, applied in the field of vaccines, can solve the problems of blood supply system function decline, cardiovascular and cerebrovascular damage, pathogenic microorganism infection, etc., and achieve the effect of preventing recurrence or reinfection, strengthening the effect, and eliminating the virus

Inactive Publication Date: 2018-07-06
西安华洲生物科技有限公司
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Long-term low-virulence infection will cause the immune system to gradually adapt to this infection. In the case of low immunity, the corresponding immune response cannot be caused against it, resulting in immune tolerance. The body cannot recognize the relevant pathogenic microorganisms, which will lead to pathogenic microorganisms. Long-term persistent infection, causing long-term damage to the body
[0004] This type of infection will cause serious pathological damage to the cardiovascular and cerebrovascular, and the continuous damage of vascular endothelial cells will cause diseases of the vascular system; the destruction of the vascular endothelium will form microthrombi, and the formation of microthrombi will block capillaries, resulting in the slow function of vascular cells. Regression, the progressive damage of blood vessels slowly accumulates, changing from quantitative deformation to qualitative change. Once a breakthrough occurs, the damage to organ function is irreversible; it will lead to a decline in the function of the blood supply system, and damage to blood vessel function will lead to diseases such as coronary heart disease.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of coronary heart disease vaccine based on (M)T-DC (Target-dendritic cell) technology

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0017] The present invention will be described in detail below in combination with specific embodiments.

[0018] Targeted dendritic cell therapy (Target-Dendritic Cell, T-DC) is to collect autologous peripheral blood mononuclear cells, and add other cytokines in the laboratory to obtain transformed dendritic cells (dendritic cells) with strong antigen-presenting function. , DC). The day before the reinfusion, a specially synthesized single-epitope polyantigen peptide is added, and the DC recognizes and captures the single-epitope polyantigen peptide to obtain mature dendritic cells that are sensitized to the patient's infectious agent virus. Migration and immune activity, go deep into the deep part of the lesion and the surrounding diseased tissue, induce the body to produce a large number of cytotoxic T lymphocytes that have a killing effect on specific antigens, thereby specifically clearing the free virus and intracellular virus in the deep layer of infection and around it...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to application of coronary heart disease vaccine based on a (M)T-DC (Target-dendritic cell) technology. An autologous dendritic cell preparation is obtained by using specific single-epitope multiple antigen peptides for in-vitro sensitization of dendritic cell, is jointly used with mesenchymal stem cells to repair vascular endothelium damaged cells and serves as venous re-transfusion type coronary heart disease vaccine. Removal of a vascular endothelial infection factor is interfered by the (M)T-DC technology, the vaccine can penetrate into the local lesion in a targetedway, corresponding treatment courses of mesenchymal stem cell treatment with multidirectional differentiation potential is also adopted, so as to repair blood vessel endothelium, and cicatrix is dissolved, so that the treatment aim is fulfilled.

Description

technical field [0001] The invention relates to a vaccine, in particular to the application of a coronary heart disease vaccine based on (M)T-DC technology. Background technique [0002] Coronary heart disease, full name coronary atherosclerotic heart disease, is also known as the first killer of human beings. According to the statistics of the World Health Organization, about 17 million people die from coronary heart disease every year in the world, accounting for more than 50% of the death toll from the disease. There are as many as 60 million patients with coronary heart disease in my country, and now it has become a fatal disease for middle-aged and even young people in the world. It is caused by coronary atherosclerosis that causes stenosis or occlusion of the vascular lumen, causing myocardial ischemia, hypoxia, and even partial myocardial necrosis. disease. It mostly occurs after the age of 40, more men than women, and more mental workers. Divided into five types: a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/00A61P9/10
CPCA61K39/0005A61K2039/572
Inventor 闫小君闫龙
Owner 西安华洲生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products